NX-1607, an inhibitor of the CBL-B E3 ubiquitin ligase, promotes favorable local and systemic changes in infiltrating immune cells in multiple mouse tumor models

Inhibitors of the E3 Ubiquitin Ligase CBL-B Promote Potent T and NK Cell Mediated Anti-Tumor Response

First Targeted Protein Degrader for Hematologic Malignancies

Discovery and Optimization of CBL-B Inhibitors

Exploring NX-5948: A CNS Penetrant Selective Degrader of BTK that Significantly Reduces Inflammation in Mouse Models of Autoimmune Disease

A First-in-Human Phase 1 Trial of NX-5948, an Oral BTK Degrader, in Patients with Relapsed and Refractory B-cell Malignancies

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Oral BTK Degrader With Immunomodulatory Activity, in Patients With Relapsed and Refractory B-Cell Malignancies

The CBL-B Inhibitor, NX-0255, Enhances Human Drug-Enhanced Tumor-Infiltrating Lymphocyte (DeTIL) Expansion and T Cell Function in Full-Scale Runs

A Phase 1 Adoptive Cell Therapy Using Drug-Enhanced, Tumor-Infiltrating Lymphocytes, DeTIL-0255, in Adults With Advanced Malignancies

Modeling Limit of Detection for Dominant T Cell Receptor Clones Reveals Comparable Measures Across RNA and DNA Based Sequencing